VOR Quote, Financials, Valuation and Earnings

Moderna has a net margin of -- compared to Vor Biopharma's net margin of -907.48%. Vor Biopharma's return on equity of -- beat Moderna's return on equity of -29.23%.

Vor Biopharma has a consensus price target of $1.18, signalling downside risk potential of -44.58%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Vor Biopharma, analysts believe Moderna is more attractive than Vor Biopharma.

Vor Biopharma has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Vor Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Vor Biopharma quarterly revenues are --, which are smaller than Moderna quarterly revenues of $107M. Vor Biopharma's net income of -$32.5M is higher than Moderna's net income of -$971M. Notably, Vor Biopharma's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma is -- versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology has a net margin of -- compared to Vor Biopharma's net margin of 6.46%. Vor Biopharma's return on equity of -- beat Puma Biotechnology's return on equity of 52.9%.

Vor Biopharma has a consensus price target of $1.18, signalling downside risk potential of -44.58%. On the other hand Puma Biotechnology has an analysts' consensus of $3.00 which suggests that it could fall by -12.79%. Given that Vor Biopharma has more downside risk than Puma Biotechnology, analysts believe Puma Biotechnology is more attractive than Vor Biopharma.

Vor Biopharma has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.736%.

Vor Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma pays -- of its earnings as a dividend. Puma Biotechnology pays out -- of its earnings as a dividend.

Vor Biopharma quarterly revenues are --, which are smaller than Puma Biotechnology quarterly revenues of $46M. Vor Biopharma's net income of -$32.5M is lower than Puma Biotechnology's net income of $3M. Notably, Vor Biopharma's price-to-earnings ratio is -- while Puma Biotechnology's PE ratio is 4.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma is -- versus 0.73x for Puma Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

PureTech Health PLC has a net margin of -- compared to Vor Biopharma's net margin of --. Vor Biopharma's return on equity of -- beat PureTech Health PLC's return on equity of --.

Vor Biopharma has a consensus price target of $1.18, signalling downside risk potential of -44.58%. On the other hand PureTech Health PLC has an analysts' consensus of $53.25 which suggests that it could grow by 186.29%. Given that PureTech Health PLC has higher upside potential than Vor Biopharma, analysts believe PureTech Health PLC is more attractive than Vor Biopharma.

Vor Biopharma has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PureTech Health PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vor Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PureTech Health PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma pays -- of its earnings as a dividend. PureTech Health PLC pays out -- of its earnings as a dividend.

Vor Biopharma quarterly revenues are --, which are smaller than PureTech Health PLC quarterly revenues of --. Vor Biopharma's net income of -$32.5M is higher than PureTech Health PLC's net income of --. Notably, Vor Biopharma's price-to-earnings ratio is -- while PureTech Health PLC's PE ratio is 8.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma is -- versus 309.63x for PureTech Health PLC. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -- compared to Vor Biopharma's net margin of -271.3%. Vor Biopharma's return on equity of -- beat Spero Therapeutics's return on equity of -108.26%.

Vor Biopharma has a consensus price target of $1.18, signalling downside risk potential of -44.58%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 102.43%. Given that Spero Therapeutics has higher upside potential than Vor Biopharma, analysts believe Spero Therapeutics is more attractive than Vor Biopharma.

Vor Biopharma has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Vor Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Vor Biopharma quarterly revenues are --, which are smaller than Spero Therapeutics quarterly revenues of $5.1M. Vor Biopharma's net income of -$32.5M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Vor Biopharma's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma is -- versus 4.76x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.